

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
29 September 2022 (29.09.2022)



(10) International Publication Number
WO 2022/200982 A1

(51) International Patent Classification:

A61K 31/4155 (2006.01) A61K 31/58 (2006.01)
A61K 31/4166 (2006.01) A61K 45/06 (2006.01)
A61K 31/4439 (2006.01) A61P 35/04 (2006.01)
A61K 31/5025 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(21) International Application Number:

PCT/IB2022/052536

(22) International Filing Date:

21 March 2022 (21.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(30) Priority Data:

63/165,723 24 March 2021 (24.03.2021) US
63/282,163 22 November 2021 (22.11.2021) US
63/317,368 07 March 2022 (07.03.2022) US

(71) Applicants: **PFIZER INC.**, [US/US]; 235 East 42nd Street,
New York, New York 10017 (US). **ASTELLAS PHAR-**
MA INC., [JP/JP]; 2-5-1, Nihonbashi-Honcho, Chuo-Ku,
Tokyo 103-8411 (JP).

(72) Inventors: **CZIBERE, Akos Gabor**; c/ Pfizer Inc.,
610 Main Street, Cambridge, Massachusetts 02139 (US).
KENNEDY, Dana Ann; c/o Pfizer Inc., 10777 Science
Center Drive, San Diego, California 92121 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; Pfizer Inc., 100 Route 206
North, Mail Stop: SOM-PPK4-LLA-403, Peapack, New
Jersey 07977 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: COMBINATION OF TALAZOPARIB AND AN ANTI-ANDROGEN FOR THE TREATMENT OF DDR GENE MU-
TATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

(57) Abstract: This invention relates to combination therapies comprising talazoparib, or a pharmaceutically acceptable salt thereof, and an anti-androgen, or a pharmaceutically acceptable salt thereof, and associated pharmaceutical compositions, methods of treatment, and pharmaceutical uses for the treatment of metastatic castration-sensitive prostate cancer in subjects identified as having at least one DNA damage repair gene mutation.

WO 2022/200982 A1